Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CVM vs CRIS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)

CVM Overall Winner 6-Pillar Tally: CVM 3 – 2 CRIS (1 Tie) Matrix Metrics: CVM 8 – 1 CRIS

As of Nov 16, 2026, Cel-Sci Corporation (CVM) is the stronger overall head-to-head candidate over Curis Inc (CRIS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas CRIS carries 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin).

  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile CRIS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs CRIS
CVM NYSE American Head-to-Head Winner
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66
CRIS NASDAQ
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap $3.8M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 11.40β · 269% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 15.0 Fund 41.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -37.9%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $0.58 · SMA50: $0.75

6-Pillar Scorecard Institutional Category Breakdown (CVM 3 – 2 CRIS)

Columns: Metric · CVM · CRIS
1. Valuation Multiples CVM
Forward P/E 23.0x N/M
Trailing P/E 23.0x 0.4x
PEG Ratio 1.12x N/M
EV / Revenue N/M N/M
2. Growth & Scale CVM
Revenue Growth (YoY) -62.7% -66.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 $4.3M
Market Cap $20.9M $3.8M
3. Profitability & Quality CVM
Gross Margin N/A N/A
Operating Margin 0.0% -833.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -252.5% -693.9%
4. Balance Sheet & Cash Flow CRIS
Cash Generation (TTM) -$17M -$36M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $4.0M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRIS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (8) vs CRIS (1)
Institutional Metric CVM CRIS Criterion Row Edge
Market Capitalization
Scale
$20.9M $3.8M Larger Scale CVM
Trailing P/E Ratio
Valuation
23.0x 0.4x Lower Multiple CRIS
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% -66.0% Higher Growth CVM
Operating Margin (TTM)
Profitability
0.0% -833.4% Higher Margin CVM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-252.5% -693.9% Higher ROE CVM
52-Week Range Position
Momentum
10% ($1–$8) 4% ($0–$7) Stronger Trend CVM
Beta / 30D Volatility
Risk Regime
0.65β · 120% Vol 11.40β · 269% Vol Lower Realized Risk CVM
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$36M EBITDA ($4.0M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRIS +19.3 pp
CVM: -11.17% · CRIS: +8.13%
3M Horizon CVM +74.11 pp
CVM: +0.0% · CRIS: -74.11%
6M Horizon CVM +0.73 pp
CVM: -7.56% · CRIS: -8.29%
1Y Horizon CRIS +9.08 pp
CVM: -75.98% · CRIS: -66.9%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue CRIS Revenue CVM Op. Margin CRIS Op. Margin Margin Leader
FY2018 N/A $10M N/A -281.3% CRIS
FY2019 N/A $10M N/A -243.5% CRIS
FY2020 N/A $10M N/A -229.8% CRIS
FY2021 N/A $10M N/A -395.0% CRIS
FY2022 N/A $10M N/A -521.7% CRIS
FY2023 N/A $10M N/A -482.2% CRIS
FY2024 N/A $10M N/A -408.3% CRIS
FY2025 N/A $10M N/A -60.5% CRIS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRIS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRIS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRIS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -833.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs CRIS Key Questions & Quantitative Answers

As of Nov 16, 2026, Cel-Sci Corporation (CVM) is the stronger overall head-to-head candidate over Curis Inc (CRIS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas CRIS carries 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile CRIS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRIS at -66.0% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (N/A gross margin, -833.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CVM cumulative revenue shifted N/A while CRIS shifted +0.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRIS.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas CRIS trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus CRIS (-693.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, CRIS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.40β · 269% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.